Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol, Safa Najidh, Shufeng Li, Armando N Bastidas Torres, Erica B Wang, Melba Herrera, Tarek I Bandali, David M Kurtz, Youn H Kim, Michael S Khodadoust

Blood blood.2024024817.

https://doi.org/10.1182/blood.2024024817

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Elizabeth Kathryn Herrity, Tommy Alfaro, Mariana Pinto Pereira, Igor Novitzky-Basso, Wilson Lam, Ivan Pasic, Fotios Michelis, Arjun D. Law, Auro Viswabandya, Adam Smith, Anne Maria Tierens, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 2206.

https://doi.org/10.1182/blood-2023-187145

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Michi M Shinohara, Youn H. Kim, Kevin Molloy, Pietro Quaglino, Julia Scarisbrick, Susan R. Thornton, Kerry Sandilands, Jen E Liu, Annabel Nixon, Angela Williams, Pablo L. Ortiz-Romero

Blood (2023) 142 (Supplement 1): 1704.

https://doi.org/10.1182/blood-2023-188808

Published: 2023

Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Blood (2023) 142 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2023-184898

Published: 2023

Journal Articles

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Yomna Eissa, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Wilson Lam, Jose-Mario Capo-chichi, Arjun D. Law, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2023-185951

Published: 2023

Journal Articles

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2023-188135

Published: 2023

Journal Articles

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Salman Basrai, Robert Kridel, Mehran Bakhtiari, Dennis D. H. Kim, Fernando L. Scolari, Filio Billia, Andrea Arruda, Mark D. Minden, Sagi Abelson

Blood (2023) 142 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2023-173489

Published: 2023

Journal Articles

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2023-190775

Published: 2023

Journal Articles

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Blood (2023) 142 (Supplement 1): 185.

https://doi.org/10.1182/blood-2023-173806

Published: 2023

Journal Articles

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Anne Lucero, Gopila Gupta, May Chiu, Filza Gul, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2023-187689

Published: 2023

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Yomna Eissa, Eshrak Al-Shaibani, Carol Chen, Shiyi Chen, Igor Novitzky-Basso, Arjun D. Law, Wilson Lam, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Ivan Pasic, Dennis D. H. Kim, Jeffrey H. Lipton, Jonas Mattsson, Rajat Kumar

Blood (2023) 142 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2023-181118

Published: 2023

Journal Articles

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Ho-Jae Han, Eun-Ju Park, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6336.

https://doi.org/10.1182/blood-2023-185440

Published: 2023

Journal Articles

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S. Khodadoust, Eric Mou, Youn H. Kim

Blood (2023) 141 (7): 695–703.

https://doi.org/10.1182/blood.2020008241

Published: 2023

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic

Blood (2022) 140 (Supplement 1): 1491–1492.

https://doi.org/10.1182/blood-2022-166916

Published: 2022

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Eric Mou, Sebastian Fernandez-Pol, Shufeng Li, Youn H. Kim, Michael S. Khodadoust

Blood (2022) 140 (Supplement 1): 6552–6553.

https://doi.org/10.1182/blood-2022-158610

Published: 2022

Journal Articles

Germline Testing for Patients with Familial MPN: A Single-Center Experience

Safa Ansar, Janet Malcolmson, Kirsten M Farncombe, Karen Yee, Raymond H Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6879–6880.

https://doi.org/10.1182/blood-2022-162430

Published: 2022

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

NARROW

Genetic alteration of class I HLA in cutaneous T-cell lymphoma

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas

Germline Testing for Patients with Familial MPN: A Single-Center Experience

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only